A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

To join this study, you would generally need to be between 50 and 90 years old and have been diagnosed with 'wet' age-related macular degeneration (AMD). Your study eye should have vision within a certain range to be included, and you must have received anti-VEGF treatments for your wet AMD in the past, and shown some positive response to them.

There are also reasons why someone might not be able to join. For example, if you have another eye condition that could affect your vision or make it hard to assess the treatment, or if you've recently had an eye infection. You also can't have poorly controlled glaucoma, a history of certain eye inflammations, or be currently using steroid eye drops in the study eye. You also can't have received gene therapy in the past, or have other serious health issues that might make it difficult to take part in the study or attend follow-up appointments.

If you decide to take part, you'll receive a single injection of either SAR402663 or a dummy treatment (called a 'diluent') into one eye. This is a blind study, meaning neither you nor your doctors will know which treatment you've received, to ensure accurate results. After the injection, you'll have regular check-ups for 12 months. These check-ups will involve various tests to monitor your eye health and vision, and to see how you're responding to the treatment.

Following these 12 months, some participants will continue into an 'extended follow-up' phase for up to 5 years. During this longer period, the main goal will be to monitor the treatment's safety and see how long any potential benefits last. The total duration of your participation could therefore be up to 5 years, with more frequent visits in the first year.